Cargando…
Protein Tyrosine Phosphatase Receptor Gamma as Potential Therapeutic Target for Chronic Myeloid Leukemia Patients
The worldwide CML incidence expects 100,000 patients every year thus representing a substantial health burden. A year 2000 is notable year, where Tyrosine kinase inhibitors (TKIs) had been introduced to the CML treatment plan. However, despite the dramatically reduce in mortality rate of CML patient...
Autores principales: | Ismail, Mohamed A., Sorio, Claudio, Al-Dewik, Nader |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9677154/ https://www.ncbi.nlm.nih.gov/pubmed/36382578 http://dx.doi.org/10.1177/10732748221140201 |
Ejemplares similares
-
Predictive value of tyrosine phosphatase receptor gamma for the response to treatment tyrosine kinase inhibitors in chronic myeloid leukemia patients
por: Ismail, Mohamed A., et al.
Publicado: (2021) -
A new monoclonal antibody detects downregulation of protein tyrosine phosphatase receptor type γ in chronic myeloid leukemia patients
por: Vezzalini, Marzia, et al.
Publicado: (2017) -
Regulative Loop between β-catenin and Protein Tyrosine Receptor Type γ in Chronic Myeloid Leukemia
por: Tomasello, Luisa, et al.
Publicado: (2020) -
Current Views on the Interplay between Tyrosine Kinases and Phosphatases in Chronic Myeloid Leukemia
por: Boni, Christian, et al.
Publicado: (2021) -
The Role of the Tumor Suppressor Gene Protein Tyrosine Phosphatase Gamma in Cancer
por: Boni, Christian, et al.
Publicado: (2022)